Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review

Current Oncology 2026 Open access

Read full text
Authors: Khashayar Yazdanpanah Ardakani, Gaia Passarella, Andrea Lania, Thoma Dario Clementi, Alessandro Fanti, Francesca Fulvia Pepe, Serena Capici, Marina Elena Cazzaniga
DOI: 10.3390/curroncol33010028
Cited by: 2
References: 40

Abstract

Pembrolizumab, an anti-PD-1 monoclonal antibody, showed promising results in the treatment of different types of solid tumors and generally an improvement in overall survival and patients' outcome. However, as a drug that targets the immune system to enhance the anti-tumor response, it simultaneously increases the risk of autoimmune reactions, producing immune-related adverse events (irAEs). These irAEs might involve any body organ, and in some cases may lead to treatment discontinuation. In this article, we discuss two cases of triple-negative breast cancer (TNBC) patients, who developed irAEs during the course of neoadjuvant pembrolizumab, highlighting the mechanism of the reactions, possible clinical manifestations, and potential management.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Chemotherapy-related skin toxicity Colorectal and Anal Carcinomas

Publication details

Journal / source
Current Oncology
Publisher
MDPI AG
Volume
33
Issue
1
Pages
28–28
Publication date
4 January 2026
Language
EN